Gastroparesis Market Report 2026

The gastroparesis market size has grown strongly in recent years. It will grow from $7.15 billion in 2025 to $7.52 billion in 2026 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to diabetes-related gastric disorders, use of antiemetic medications, hospital-based gi care, dietary management approaches, availability of diagnostic imaging.

The gastroparesis market size is expected to see strong growth in the next few years. It will grow to $9.29 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to innovation in implantable stimulation devices, growth in outpatient treatment models, rising diabetic population, demand for symptom-focused therapies, improved clinical awareness. Major trends in the forecast period include increased use of prokinetic medications, growing adoption of gastric electrical stimulation devices, rising focus on dietary and lifestyle management, expansion of minimally invasive surgical options, improved diagnosis of diabetic gastroparesis.

The rapid increase in diabetes prevalence is expected to drive the growth of the gastroparesis market in the coming years. Diabetes is a chronic condition characterized by elevated blood glucose levels due to the body’s inability to produce sufficient insulin or effectively use the insulin it produces. Diabetes significantly raises the risk of developing gastroparesis, as it increases the population susceptible to this condition. For example, in April 2025, the International Diabetes Federation, a Belgium-based advocacy organization, reported that nearly one in nine adults globally (589 million) are living with diabetes. Of these, an estimated 252 million are unaware of their condition, placing them at higher risk of serious complications and premature death. Therefore, the rapid rise in diabetes prevalence is driving the gastroparesis market.

Key companies in the gastroparesis market are developing drugs to enhance their market presence and address symptoms associated with delayed stomach emptying. For instance, in December 2023, Vanda Pharmaceuticals Inc., a US-based biopharmaceutical company, reported that the U.S. FDA accepted the New Drug Application for Tradipitant, a potential treatment for gastroparesis. The FDA has scheduled a decision date for Tradipitant under the Prescription Drug User Fee Act (PDUFA) on September 18, 2024. If approved, Tradipitant would become the first FDA-approved novel drug for gastroparesis in over 40 years, marking a significant milestone in more than three decades for a drug to undergo FDA review specifically for this condition.

In May 2025, Dr. Falk Pharma, a Germany-based specialty pharmaceutical company focused on gastroenterology, partnered with Renexxion to advance the development and commercialization of innovative gastrointestinal therapies. Through this collaboration, Dr. Falk Pharma and Renexxion aim to advance the clinical development and global commercialization of naronapride, a precision therapy for gastroparesis that combines regulatory expertise with novel prokinetic technology. Renexxion, a U.S.-based clinical-stage biotech company, is focused on developing naronapride, a selective 5-HT4 agonist designed to enhance gastric motility in patients with gastroparesis.

Major companies operating in the gastroparesis market are Pfizer Inc., GlaxoSmithKline plc., Abbott Laboratories Inc., AstraZeneca Plc., Medtronic Plc., Takeda Pharmaceutical Company Limited, Johnson And Johnson Services Inc., Teva Pharmaceutical Industries Ltd, AbbVie Inc., Boston Scientific Corporation, Cadila Pharmaceuticals Ltd., Daewoong Pharmaceutical Co. ltd, ANI Pharmaceuticals Inc., Dompe Farmaceutici S.p.A, Sucampo Pharmaceuticals Inc., Ironwood Pharmaceuticals Inc., RedHill Biopharma Ltd., CinRx Pharma LLC, Ritter Pharmaceuticals Inc., Evoke Pharma Inc., Metacrine Inc., Neurogastrx Inc.

North America was the largest region in the gastroparesis market in 2025. The regions covered in the gastroparesis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gastroparesis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the gastroparesis market by increasing costs of imported medical devices, pharmaceuticals, and diagnostic equipment. Hospitals and specialty clinics are most affected due to reliance on imported therapies. These tariffs increase treatment costs by raising expenses for gastric stimulation devices, prokinetic drugs, and diagnostic procedures, limiting access to advanced care options. However, they support domestic production of medical devices, strengthening regional manufacturing of gastrointestinal treatment technologies.

The gastroparesis market research report is one of a series of new reports that provides gastroparesis market statistics, including gastroparesis industry global market size, regional shares, competitors with a gastroparesis market share, detailed gastroparesis market segments, market trends and opportunities, and any further data you may need to thrive in the gastroparesis industry. This gastroparesis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gastroparesis is a medical disorder characterized by weakened or impaired stomach muscles, leading to delayed emptying of stomach contents into the small intestine. Treatment for gastroparesis includes medications to stimulate stomach emptying, manage underlying conditions, and surgical interventions.

The primary treatment approaches for gastroparesis include medications, dietary modifications, medical devices, and others. Medications are substances that interact with the body’s biological processes to produce a therapeutic effect. Medications such as prokinetic drugs, antiemetics, botulinum toxin injections, antidepressants, and others are used to diagnose, treat, manage, or prevent gastroparesis. They are employed in the treatment of idiopathic, diabetic, post-surgical, and other types of gastroparesis in both pediatric and adult patients. These medications are distributed through retail pharmacies, hospital pharmacies, and others, and are utilized by hospitals, clinics, ambulatory surgical centers, and home care settings.

The gastroparesis market consists of sales of metoclopramide, domperidone, and erythromycin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.